Cite
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
MLA
Nathalie Meuleman, et al. Pomalidomide plus Low-Dose Dexamethasone Is Active and Well Tolerated in Bortezomib and Lenalidomide-Refractory Multiple Myeloma: Intergroupe Francophone Du Myélome 2009-02. Jan. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....478bbc84c09672da4e6d6925c2114835&authtype=sso&custid=ns315887.
APA
Nathalie Meuleman, Laurent Garderet, Philippe Moreau, Sabine Brechignac, Brigitte Kolb, Gerald Marit, Margaret Macro, Hervé Avet-Loiseau, Michel Attal, Bruno Royer, Mauricette Michallet, Murielle Roussel, Marie Odile Petillon, Claire Mathiot, Beatrice Thielemans, Martine Escoffre-Barbe, Olivier Decaux, Intergroupe Francophone du Myelome, Xavier Leleu, … Denis Caillot. (2013). Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Chicago
Nathalie Meuleman, Laurent Garderet, Philippe Moreau, Sabine Brechignac, Brigitte Kolb, Gerald Marit, Margaret Macro, et al. 2013. “Pomalidomide plus Low-Dose Dexamethasone Is Active and Well Tolerated in Bortezomib and Lenalidomide-Refractory Multiple Myeloma: Intergroupe Francophone Du Myélome 2009-02,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....478bbc84c09672da4e6d6925c2114835&authtype=sso&custid=ns315887.